BIoLink -- BioPharm Innovation and International Technology Transfer Summit 2015 was Held in Beijing
The first BIoLink -- BioPharm Innovation and International Technology Transfer Summit (hereinafter referred to as BioLink Summit), co-organized by China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE), UBM Sinoexpo International Exhibition Co.Ltd and Beijing Yizhuang Biomedical Park, was held in Beijing Yizhuang Biomedical Park on January 22-23, 2015. The summit aimed to bring together the talents, products and technologies in bio-pharmacy industry both at home and abroad as well as building a platform for technology transfer and medicine service and bringing new thoughts and ideas to China’s bio-pharmacy industry in its integrating into the international market. Participants included leading biopharmaceutical companies in China and in the world such as Johnson & Johnson Innovation, Sanofi-Aventis, Bayer, CNBG, Hualan Biological Engineering INC, Luye Pharma Group and Sino Biopharmaceutical Ltd, etc, governments and agencies at home and abroad such as UK Medicines and Healthcare Products Regulatory Agency, WHO, BMGF Beijing Office, PATH and RDPAC, etc. More than 210 representatives attended the meeting.
The BioLink Summit was formally opened on the afternoon of January 22. Mr. Licheng Sheng, Deputy Director of BDA Administrative Commission from Beijing Ecomonic-Technological Development Area, made opening remarks. Opening addresses entitled “Analysis on the international competitiveness of China’s bio-medical industry” and “Building a World-class innovative Biologics Industry in China” were respectively delivered by Dr.Ming Xu, Vice President of CCCMHPIE and Joseph Cho, Managing Director of RDPAC. In the “Keynote Speech” section, Bing Zeng, Deputy General Manager of Sinopharm Group, Dr. Julian Bonnerjea, Head of the Biologicals Unit of the UK Medicines and Healthcare Products Regulatory Agency and Dr. Yinxiang Wang, CEO and Chief Scientistic Officer of Betta pharmaceuticals delivered speeches respectively. Dr. Mingde Xia, Senior Director of New Ventures of Johnson & Johnson Innovation acted as the chairman of this summit.
On January 23, BioLink Summit was stepped into the “Panel Discussion” part. Dr. Bernhard Schwartlander, WHO Representative in China, gave a speech. Hosted by Jack Zhang, China Representative of PATH, a discussion on the “Engage China Vaccine Stakeholders for WHO Vaccine Prequalification and GAVI Markets” was made by Dr. Bernhard Schwartlande, Dr. Ray Yip, BMGF Beijing Office, Yonglin Wu, Vice President of CNBG, HaifaZheng, CEO of Beijing Minhai Biotechnology Co.,Ltd and Kang An, Chairman & Director of Hualan Biological Engineering INC. The following panel discussion entitled “Driving Strategic Innovative Partnering to Overcome R&D Challenges in China” was chaired by Dr. Mingde Xia, Senior Director of New Ventures of Johnson & Johnson Innovation. Panelists in this section were Dr. Yi YANG, Director of Preclinical Safety from Sanofi (China), Will Liu, Head of Innovation China of Merck Serono, Dr. Ke Wu，CEO of Shanghai BravoBio Co., Ltd, Dr. Sammy Jiang, VP of Luye Pharma Group, Dr. Lijie Zhang, VP of Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd and Dr. Haizhou Zhang from the Center of Medical and Translational Sciences of CP Guojian Pharm. The third theme of the “Panel Discussion” was “Enhancing Collaborations between Pharma and Investors on Expanding R&D Budgets”. Panelists in this section were Xiaoyang Xu, CEO of Sino Biopharmaceutical Ltd, Maykin Ho，Advisory Director of Goldman Sachs (Asia) LLC, Forest Xu, Partner of WI Harper Group and Eric Yan, Manager of L.E.K. Consulting. The moderator of this part was Cherrie Che, Head of BHC Strategy and Sales Excellence of China Bayer Healthcare Co., Ltd.
And on January 23, at the same time with the BioLink Summit, there was also a BIoLink International Technology Transfer Projects and Match Making Meeting, in which more than 30 projects such as pegylated interferon λ chimera for chronic hepatitis B and influenza, FGF18 chimera for osteoarthritis and cartilage repair and so on were transferred and matched.
The BioLink Summit Hall
Guests of the Summit
Speakers
Panel Discussion